Cerveau Technologies Inc. today announced a research collaboration with University College London (UCL), a leading UK academic center for the production and application of imaging biomarkers for use in clinical research, that grants the institution the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. The facility has been fully qualified by Cerveau to produce the tracer. This will facilitate clinical studies at UCL and associated centers of excellence for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease [ABSTRACT FROM PUBLISHER]
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
